Dogwood Therapeutics Inc. (DWTX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Dogwood Therapeutics Inc. (NASDAQ: DWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.22 (-4.69% 1D, market cap $43.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, DWTX ranks #515 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DWTX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.3%. By comparison, ELTX (Elicio Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $45.5M) and MREO (Mereo BioPharma Group plc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M). Among the 5-stock peer group, DWTX leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).
Per DWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818844), Dogwood Therapeutics Inc. generated $78.3M in revenue (+128.7% YoY), -$34.3M in net income, and -$15.6M in free cash flow against $90.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 45.3 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While DWTX currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.63) and Max Pain ($1.28) forces dealer call-delta covering toward $7.39.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Dogwood Therapeutics Inc. (DWTX) dropped -4.69% to $1.22, trading at 3% of its 52-week range ($1.07 – $7.04). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
https://www.sec.gov/Archives/edgar/data/1818844/000110465926120650/tm2628568d1_s3.htm
- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 -- Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +128.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DWTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DWTX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Dogwood Therapeutics Inc. (DWTX) ranks #515 by composite RQD confidence (38/100, grade D-) and #764 by equity capitalization ($43.5M). Within this direct 5-issuer industry benchmark cohort, DWTX leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. DWTX currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DWTX
ACTIVE
Dogwood Therapeutics Inc. | D- | 38/100 | — | — | -32.3% | -4.69% | $43.5M | Benchmark Subject |
| ELTX Elicio Therapeutics Inc. | E | 28/100 | — | — | -35.0% | -5.36% | $45.5M | /eltx-vs-dwtx → |
| MREO Mereo BioPharma Group plc | D- | 37/100 | — | — | -35.0% | +0.17% | $46.2M | /mreo-vs-dwtx → |
| BMEA Biomea Fusion Inc. | E | 30/100 | — | — | -35.0% | +3.19% | $46.4M | /bmea-vs-dwtx → |
| GRCE Grace Therapeutics Inc. | E | 32/100 | — | — | -18.9% | -6.70% | $40.8M | /grce-vs-dwtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dogwood Therapeutics Inc. (DWTX) reported GAAP revenue of $78.3M (+128.7% vs. FY2024 revenue of $34.2M , and +413.5% cumulative change since FY2023) , GAAP net income of -$34.3M, operating cash flow of -$15.6M, and free cash flow of -$15.6M (-77.7% YoY). On the balance sheet, DWTX closed FY2025 with $90.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $78.3M | -$34.3M | -$15.6M | -$15.6M | $90.2M | — |
| FY2024 (FY) | 2024-12-31 | $34.2M | -$12.3M | -$8.8M | -$8.8M | $94.3M | — |
| FY2023 (FY) | 2023-12-31 | $15.3M | -$5.3M | -$4.9M | -$4.9M | — | — |
As of 2026-11-03, Dogwood Therapeutics Inc. (NASDAQ: DWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.22 (-4.69% 1D, market cap $43.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, DWTX ranks #515 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DWTX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.3%. By comparison, ELTX (Elicio Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $45.5M) and MREO (Mereo BioPharma Group plc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M). Among the 5-stock peer group, DWTX leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).
Per DWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818844), Dogwood Therapeutics Inc. generated $78.3M in revenue (+128.7% YoY), -$34.3M in net income, and -$15.6M in free cash flow against $90.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
DWTX last traded at $1.22 (-4.69% on volume of 39,038 shares), positioning the stock -25.15% below its 50-day simple moving average ($1.63) and -37.76% below its 200-day simple moving average ($1.96). Across its 52-week range of $1.07 to $7.04, DWTX sits at the 2.5% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.07 to $1.37).
Dogwood Therapeutics Inc. (DWTX) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.22 (-4.69% 1D, market capitalization $43.5M).
Dogwood Therapeutics Inc. (DWTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Reported revenue is — in each period shown in the SEC financials, so the company is not generating revenue in the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Dogwood Therapeutics Inc. (DWTX) reported $78.3M in annual revenue (up from $34.2M in FY2024, +128.7% YoY) and -$34.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($15.3M revenue, -$5.3M net income) through FY2025, DWTX scaled operating cash flow to -$15.6M and free cash flow to -$15.6M, backed by $90.2M in total assets against $0 in total debt.
The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations for DWTX. A prospective investor should note that the one identifiable second-order dependency is financing: the company's runway, as described in the news items, depends on the private placement and the timing of the planned share sale. Watch for how the 4.1 million-share sale affects supply and price, and for whether trial timing aligns with the stated funding horizon.
Real-time company headlines, analyst actions, and sector developments for Dogwood Therapeutics Inc. (DWTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Dogwood Therapeutics Inc. (DWTX) market action, institutional positioning, and fundamental catalysts.
https://www.sec.gov/Archives/edgar/data/1818844/000110465926120650/tm2628568d1_s3.htm
The street is overcomplicating Dogwood Therapeutics Inc. (DWTX). A $5 million private placement is reported as funding the company through March 2027 as it plans its next pain-drug trial.. With an RQD score of 38/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.38.
Both sides have a point here — DWTX's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
I respect the product at Dogwood Therapeutics Inc., but the stock at $1.28 is a different story. The company reports zero revenue, -32.3% ROIC, and FY 2025 cash falling to $6.5M against -$15.6M of free cash flow, with a planned 4.1 million-share sale adding dilution pressure.. FCF yield is 0.0% and RQD sits at 38/100 (D-) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: